Supported by

Aptadel is supported by academic foundations, patient associations and competitive grants from national and international agencies.

Supported by

IDIBELL

Co-Founder

The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine, located in the south of Barcelona, promoted by the Bellvitge University Hospital and Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council. In 2017, the Center for Regenerative Medicine of Barcelona (CMR[B]), now part of IDIBELL, launched the Program for Advancing the Clinical Translation of Regenerative Medicine of Catalonia (P-CMR[C]) together with IDIBELL.

IDIBELL research is focused in cancer, neuroscience, translational medicine and regenerative medicine. Research, innovation and society are the axes on which researchers work every day with the goal of improving the quality of life of citizens.

Fundación Alba Pérez

Co-Founder

The Alba Perez Foundation is a Spanish foundation that aims to raise funds for the creation of scholarships, grants and/or contracts or collaboration agreements with both public and private entities for research in the fight against childhood cancer, and in particular, Ewing’s Sarcoma.

It is dedicated to the organisation, implementation and management of promotional events, dissemination, fundraising through donations from individuals, public bodies and companies in order to devote these funds to research into childhood cancers.

Project CPP2021-008515 cofunded by por MCIN/AEI /10.13039/501100011033 and European Union–Next Generation EU/PRTR

Aptadel Therapeuticsvhas been awarded with the CDTI grant SNEO-20222194, in collaboration with Ministerio de Ciencia e Innovación and cofunded by the European Union–Next Generation EU

Aptadel Therapeutics has received funding from the Eurostarts-3 joint programme, cofunded by the European Union Horizon 2020 research and innovation programme and CDTI